Contradictory evidence regarding fibrinolysis [7] and other substances, that could play an important role in the hemostatic deficits observed in the PAH setting (namely soluble thrombomodulin and plasminogen activator inhibitor-1) [36,37] have also been reported. The gene discussed is THBD; the disease is pulmonary arterial hypertension.